PATENT CLAIM ANALYSIS

Application Number: 16087918
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-10
Patent Classification: ["544", "280000"]

Abstract:
The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.

Claim (Index 17):
The method according to  claim 16 , wherein the disease associated with CDK4 and/or CDK6 inhibition comprises cancer, and the cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, kidney cancer, epidermal cancer, liver cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, gallbladder cancer, ovarian cancer, pancreatic cancer, gastric cancer, cervical cancer, thyroid cancer, rhinocarcinoma, head and neck cancer, prostate cancer, skin cancer, leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma, multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, hair cell lymphoma, Burkitt lymphoma, acute and chronic myeloid leukemia, myelodysplastic syndrome, promyelocytic leukemia, thyroid follicular cancer, fibrosarcoma, rhabdomyosarcoma, glioma, schwannoma, melanoma, seminoma, teratoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer, liposarcoma, neuroendocrine tumor and Kaposi sarcoma; and preferably, the cancer is selected from the group consisting of metastatic breast cancer, melanoma, non-small cell lung cancer, teratoma, neuroendocrine tumor and liposarcoma.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.91071
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15566872', '13497067', '14158358', '13060154', '15546165']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.807736145385747
- 35 USC 102 Novelty (BERT): 0.5344671923288448
- Combined Prediction Score: 0.7804092500800568
- Mean Citation Score: 350.99347400000005
- Max Citation Score: 367.805
- Similarity Product: 280.8690487152338

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test